[Corticosteroid as an anti-emetic agent in cancer chemotherapy with cis-diammine-dichloroplatinum (II)]

Gan To Kagaku Ryoho. 1985 Mar;12(3 Pt 1):561-5.
[Article in Japanese]

Abstract

The anti-emetic effect of corticosteroid during cancer chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) is analyzed retrospectively. From November 1981 to April 1984, 23 of 50 patients receiving CDDP were given corticosteroid as an anti-emetic. Corticosteroids, methylprednisolone (80-500 mg/day) or hydrocortisone (200-480 mg/day), were administered intravenously for 1 to 3 doses. Including 4 patients who had no symptoms, 60% of patients were free from nausea and vomiting. The incidence of gastrointestinal symptoms was significantly lower than that in patients who were not given corticosteroid. Corticosteroid reduced gastrointestinal symptoms in 2 of 3 patients who had prior CDDP treatment. There were no remarkable adverse reactions except acne in 2 patients. A further controlled study is needed to determine the appropriate dose and modality of administration of corticosteroid.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Antiemetics / therapeutic use*
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects*
  • Cisplatin / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hydrocortisone / administration & dosage
  • Hydrocortisone / therapeutic use*
  • Male
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / therapeutic use*
  • Middle Aged
  • Retrospective Studies
  • Urologic Neoplasms / drug therapy*
  • Vomiting / chemically induced
  • Vomiting / prevention & control

Substances

  • Antiemetics
  • Cisplatin
  • Hydrocortisone
  • Methylprednisolone